Cleveland startup Neuronoff implants its first patient in a US Department of Defense-funded trial of a needle-delivered nerve electrode for bladder control after spinal cord injury
Neuronoff announced on 5 June 2026 that it has implanted the first patient in a US Department of Defense-funded clinical trial of its Injectrode, a helical platinum-iridium peripheral nerve electrode delivered through a single 18-gauge needle under local anaesthesia, in patients with neurogenic bladder dysfunction following spinal cord injury. The trial (NCT07264868) is being run at UT Health Houston under principal investigator Dr Argyrios Stampas, Professor of Physical Medicine and Rehabilitation at McGovern Medical School. It is a Phase 1/2 randomised controlled study enrolling 21 participants across three arms (unilateral active stimulation, bilateral active stimulation, sham), with primary endpoints at 4 and 8 weeks assessing safety, stimulation accuracy, procedural feasibility, and physician and patient acceptability. This is the first-in-human spinal cord injury trial of the Injectrode.